You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR DUPIXENT

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for DUPIXENT

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01385657 ↗	Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis	Completed	Sanofi	Phase 1	2011-07-31	The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).
NCT01385657 ↗	Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis	Completed	Regeneron Pharmaceuticals	Phase 1	2011-07-31	The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).
NCT01548404 ↗	Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis	Completed	Sanofi	Phase 2	2012-04-01	The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).
NCT01548404 ↗	Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis	Completed	Regeneron Pharmaceuticals	Phase 2	2012-04-01	The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).
NCT01639040 ↗	Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)	Completed	Sanofi	Phase 2	2012-07-01	The purpose of this study was to assess the safety of Dupilumab administered concomitantly with topical corticosteroids (TCS) in patients with moderate-to-severe atopic dermatitis (AD).
NCT01639040 ↗	Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)	Completed	Regeneron Pharmaceuticals	Phase 2	2012-07-01	The purpose of this study was to assess the safety of Dupilumab administered concomitantly with topical corticosteroids (TCS) in patients with moderate-to-severe atopic dermatitis (AD).
NCT01859988 ↗	Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis	Completed	Sanofi	Phase 2	2013-05-01	To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for DUPIXENT

Condition Name

Chart
Table

Condition Name for DUPIXENT
Intervention	Trials
Atopic Dermatitis	20
Asthma	4
Eczema	3
Asthma, Allergic	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for DUPIXENT
Intervention	Trials
Eczema	22
Dermatitis, Atopic	22
Dermatitis	22
Asthma	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for DUPIXENT

Trials by Country

Map
Table

Trials by Country for DUPIXENT
Location	Trials
United States	217
Poland	32
Canada	25
Japan	20
United Kingdom	16
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for DUPIXENT
Location	Trials
New York	17
California	15
Florida	13
Texas	11
Michigan	11
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for DUPIXENT

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for DUPIXENT
Clinical Trial Phase	Trials
Phase 4	17
Phase 3	7
Phase 2	24
[disabled in preview]	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for DUPIXENT
Clinical Trial Phase	Trials
Recruiting	25
Not yet recruiting	13
Completed	10
[disabled in preview]	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DUPIXENT

Sponsor Name

Chart
Table

Sponsor Name for DUPIXENT
Sponsor	Trials
Regeneron Pharmaceuticals	35
Sanofi	22
National Institute of Allergy and Infectious Diseases (NIAID)	5
[disabled in preview]	9
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for DUPIXENT
Sponsor	Trials
Industry	63
Other	41
NIH	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.